NR511 CPG Presentation

NR511 CPG Presentation. This presentation is going to cover what the background of dyslipidemia is, how we should be screening for it in primary care and how we need to be managing our patients that have dyslipidemia. According to the American Heart Association’s report on heart disease and stroke statistics for 2017, the incidence of dyslipidemia has actually decreased by about 7% between the years of 1999 and 2014, which is believed to be attributed to the fact that more people with dyslipidemia are actually taking anti-lipid medication. The prevalence reported in the Clinical Practice Guidelines article on dyslipidemia put together by the American Association of Clinical Endocrinologists and the American College of Endocrinology states that as of 2012, more than 100 million US adults over the age of 20 have a total cholesterol greater than or equal to 200mg/dL and about 31 million US adults have a total cholesterol of greater than 240. They also report that about 69% of US adults have an LDL level of greater than 100, 33% have high triglyceride levels, and 38% have self-reported that they are on anti-lipid medications. A brief pathophysiology of dyslipidemia is that it is a heterogenous metabolic disorder with high cholesterol and lipid levels. With dyslipidemia, there is a known increased risk of atherosclerosis, which can lead to a myriad of complications and diseases. Dyslipidemia can be genetic or can be behavior-related, which is usually due to a poor diet and decreased physical